NCT00283101 - A Safety Study in Patients With Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions

Leukemia, Lymphocytic, Chronic

Interventions

DRUG

SGN-40 (anti-huCD40 mAb)

1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.

Trial Locations (4)

Weill Medical College/Cornell University, New York

University of Miami, Sylvester Comprehensive Cancer Center, Miami

University of Alabama at Birmingham, Birmingham

Fred Hutchinson Cancer Research Center, Seattle